Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A window of opportunity study (WOO) of pelareorep in the neoadjuvant setting for breast cancer

Trial Profile

A window of opportunity study (WOO) of pelareorep in the neoadjuvant setting for breast cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2018

At a glance

  • Drugs Pelareorep (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 18 Sep 2018 New trial record
    • 10 Sep 2018 According to an Oncolytics Biotech media release, this trial is being conducted under a collaboration between the company and SOLTI and the first patient is expected to be enrolled around the end of 2018 or very early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top